Pharma/fine chemicals roundup—24 September 2013
4:46 AM MDT | September 24, 2013 | By DEEPTI RAMESH
Cedarburg Hauser expands API capacity
Cedarburg Hauser Pharmaceuticals (CHP; Grafton, WI) says it has upgraded its active pharmaceutical ingredient (API) manufacturing plant at Grafton. The upgraded facilities are expected to facilitate a 20–25% increase in API production, CHP says. These upgrades are a continuation of a long-term capital improvement initiative that results from an increased demand for the contract manufacturing of commercial APIs, CHP says. CHP is a contract development and manufacturing organization specializing in small molecule APIs and pharmaceutical intermediates.
Lipitor inventor Bruce Roth wins Perkin Medal
The Society of Chemical Industry– America International Group (SCI; New York), last week presented the Perkin Medal, the US industry’s highest honor in applied chemistry, to Bruce Roth, for his work on research, discovery and invention of atorvastatin, the best-selling pharmaceutical marketed as Lipitor. Roth began his work on Lipitor in 1982, when he joined the atherosclerosis chemistry department at Warner-Lambert, now a part of Pfizer. As a part of a project aimed at discovering inhibitors of cholesterol biosynthesis, he synthesized the compound that would become Lipitor. Roth notes that the discovery did not come easily or cheaply. Challenges, such as multiple failures during the discovery process, lack of enthusiasm about the drug from the industry, and the fact that his team was not the first to submit a drug in the class to market, raised questions before its 1996 public launch, Roth says.
Aesica opens new facility at Queenborough site
Aesica Pharmaceuticals (Newcastle, UK) says it has opened a new high-capacity manufacturing facility following a £30-million ($48 million) investment at its Queenborough site in United Kingdom. The facility will produce solid dose medication used in treating type 2 diabetes in adults. Commercial production at the facility will begin in November. The specific product manufactured at the new facility has global sales and is set for worldwide export. The facility will have a workforce of 55 technicians and the design of the facility will allow the current capacity to be more than doubled in the future which would require an additional 50 employees.
Mitsubishi Chemical completes acquisition of Medicago
Mitsubishi Chemical Holdings says that its Mitsubishi Tanabe Pharma (Osaka) subsidiary has completed the previously announced acquisition of Canadian pharmaceutical company Medicago (Quebec City). Medicago will be operated as a joint venture owned 60% by Mitsubishi Tanabe Pharma and 40% by Philip Morris Investments (Bergen op Zoom, Netherlands).
Beyond IHS Chemical Week:
Chinese pharma intermediates may become uncompetitive compared to India
from Business Standard, India
Interview with Ashwin Shroff, chairman & managing director, Excel Industries
India is one of leading players in the global pharmaceutical industry with many companies exporting to the developed markets. In last 10-15 years, with imports becoming less costly with lowering of customs duties and other restrictions, intermediates imports from China to manufacture active pharmaceutical intermediates (APIs) have increased. Pharma companies would buy intermediates from China and add value and sell APIs and formulations. Most of the pharma companies sold their formulations in the local market, while exported bulk of APIs. In last few years, Chinese currency Yuan has appreciated against the dollar. Also, the production cost has been increasing in China with the implementation of stringent regulations and escalating labour cost. Re has also lost against the dollar in recent past. All these factors will result in increase in cost of Chinese intermediates, making them uncompetitive compared with products manufactured in India. This will offer huge business opportunities to Indian companies in the intermediate space.
Gaining insights on contract chemical API manufacturing
from Pharmaceutical Technology
Pharmaceutical Technology gained the views of chemical API manufacturers on the key issues shaping the pharmaceutical industry and their impact on supply-demand fundamentals for contract small-molecule manufacturing and the outsourced relationship. Participating in the roundtable were: Susan Daly, PhD, and API technical manager, Aesica Pharmaceuticals; Kurt Hoeprich, global business manager, pharmaceuticals, Albemarle; Brian Scanlan, CEO and president of Cambridge Major Laboratories; Mark Griffiths, CEO, the Dishman Group of Companies; and Andreas Weiler, PhD, head of global strategic marketing, contract manufacturing services and solutions, SAFC.
Mold, API contaminants prompt more J&J recalls
Johnson & Johnson is battling another onset of quality concerns as its subsidiary Janssen is pulling one lot of its Risperdal Consta injection in the US due to a mold contamination.